Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Anjarium Biosciences AG currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This specific matter is assigned to a single distinct examiner and a single distinct art unit, indicating a highly concentrated prosecution footprint. The focus of the portfolio's current activity is entirely centralized under one point of review at the patent office, which simplifies the tracking of legal deadlines and responses.
The busiest examiner for the company is BORGEEST, CHRISTINA M, who is responsible for 1 busiest examiner pending office action. Because this count matches the total workload, this specific examiner handles the entirety of the company's current applications. Practitioners can focus their strategy on the specific preferences and history of this individual examiner and the distinct art unit involved. This concentration suggests that the outcome of the current prosecution cycle depends on the interactions within a single administrative channel, allowing for a highly targeted legal approach that accounts for the examiner's specific tendencies.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555437 | FC-DERIVED POLYPEPTIDES | BORGEEST, CHRISTINA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555437 | FC-DERIVED POLYPEPTIDES | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18555437 | FC-DERIVED POLYPEPTIDES | BORGEEST, CHRISTINA M | 1675 | §103§112 | Non-Final OA | — | Pending | Oct 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial